​Hoth Therapeutics is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis. Hoth’s first focus to market therapeutics will be the Biolexa compound, a treatment for atopic dermatitis, also known as eczema. BioLexa combines two (2) FDA approved drugs in a proprietary formulation to prevent bacterial proliferation, colonization, and biofilm-related infections.